Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression

  • Authors:
    • Yoshiaki Yamamoto
    • Yutaka Suehiro
    • Atomu Suzuki
    • Ryosuke Nawata
    • Yoshihisa Kawai
    • Ryo Inoue
    • Hiroshi Hirata
    • Hiroaki Matsumoto
    • Takahiro Yamasaki
    • Kohsuke Sasaki
    • Hideyasu Matsuyama
  • View Affiliations

  • Published online on: May 24, 2017     https://doi.org/10.3892/ol.2017.6233
  • Pages: 1193-1199
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Accumulating evidence has suggested that germline DNA copy number variations (CNVs) affect various disorders, including human malignancies. However, the significance of CNVs in non‑muscle invasive bladder cancer (NMIBC) remains unclear. The purpose of the present study was to identify the role of CNVs in NMIBC. Array comparative genomic hybridization (CGH) analysis was performed to search for candidate CNVs associated with NMIBC susceptibility. Quantitative polymerase chain reaction was carried out to evaluate CNVs associated with patient outcome in 189 NMIBC cases. In total, 11 CNVs were associated with NMIBC risk in array CGH analysis. Out of the 189 CNVs examined, family with sequence similarity 81 member A (FAM81A) and proprotein convertase subtilisin/kexin type 6 (PCSK6) CNVs exhibited a significant association with recurrence and disease progression in NMIBC. PCSK6 has been reported to regulate proliferation and tumor progression in breast and prostate malignancies. Notably, patients with pT1 stage had significantly lower PCSK6 relative copy number than those with pTa (P=0.0196). In multivariate analyses, PCSK6 copy number was an independent prognostic factor for progression‑free survival (P=0.0456; risk ratio, 2.17; 95% confidence interval, 1.02‑4.82). These data suggest that PCSK6 CNV is a potential new tumor marker for estimating disease progression in NMIBC.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 14 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamamoto Y, Suehiro Y, Suzuki A, Nawata R, Kawai Y, Inoue R, Hirata H, Matsumoto H, Yamasaki T, Sasaki K, Sasaki K, et al: Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression. Oncol Lett 14: 1193-1199, 2017
APA
Yamamoto, Y., Suehiro, Y., Suzuki, A., Nawata, R., Kawai, Y., Inoue, R. ... Matsuyama, H. (2017). Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression. Oncology Letters, 14, 1193-1199. https://doi.org/10.3892/ol.2017.6233
MLA
Yamamoto, Y., Suehiro, Y., Suzuki, A., Nawata, R., Kawai, Y., Inoue, R., Hirata, H., Matsumoto, H., Yamasaki, T., Sasaki, K., Matsuyama, H."Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression". Oncology Letters 14.1 (2017): 1193-1199.
Chicago
Yamamoto, Y., Suehiro, Y., Suzuki, A., Nawata, R., Kawai, Y., Inoue, R., Hirata, H., Matsumoto, H., Yamasaki, T., Sasaki, K., Matsuyama, H."Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression". Oncology Letters 14, no. 1 (2017): 1193-1199. https://doi.org/10.3892/ol.2017.6233